Sign In
Buy ARGX
$844.50
+13.71 (+1.65%)
At Close: Aug 04, 2026
argenx announces Annual General Meeting of Shareholders on May 11, 2021
04:00pm, Tuesday, 30'th Mar 2021
March 30, 2021
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2020 Results - Earnings Call Transcript
03:18pm, Thursday, 04'th Mar 2021
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2020 Results - Earnings Call Transcript
argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update
01:00am, Thursday, 04'th Mar 2021
- Biologics License Application (BLA) for IV efgartigimod accepted for review by U.S. Food and Drug Administration (FDA) for generalized myasthenia gravis (gMG)
argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021
01:00am, Thursday, 25'th Feb 2021
February 25, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and canc
argenx announces closing of global offering
04:01pm, Friday, 05'th Feb 2021
Regulated information
argenx announces full exercise of underwriters' option to purchase additional ADSs
01:00am, Thursday, 04'th Feb 2021
Regulated information — Inside information
argenx raises $1.0 billion in gross proceeds in a global offering
10:15pm, Tuesday, 02'nd Feb 2021
Regulated information — Inside information
argenx Issues Statement Concerning Efgartigimod
09:37am, Tuesday, 02'nd Feb 2021
-No observed elevation of cholesterol markers related to treatment with efgartigimod
argenx announces launch of proposed global offering
04:01pm, Monday, 01'st Feb 2021
Regulated information — Inside information
Regulated Information/Inside Information
Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOs
03:16pm, Sunday, 10'th Jan 2021
Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth
argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline
01:00am, Friday, 08'th Jan 2021
Breda, the Netherlands – Jan. 8, 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cance
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
04:01pm, Wednesday, 06'th Jan 2021argenx to Present at 39th Annual J.P. Morgan Healthcare Conference
01:00am, Monday, 04'th Jan 2021
January 4, 2021 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune di
argenx Enters Into Agreement To Acquire Priority Review Voucher
01:00am, Monday, 23'rd Nov 2020
November 23, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune
